Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Hexal AG |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00632125 |
Cumulative follow-up with HX575 epoetin alfa to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 epoetin alfa i.v.
Condition | Intervention | Phase |
---|---|---|
Chronic Kidney Disease |
Drug: HX575 recombinant human erythropoietin alfa |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v. |
Estimated Enrollment: | 1500 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: HX575 recombinant human erythropoietin alfa
HX575 epoetin alfa i.v. will be administered according to the SmPC
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Karsten Roth, Dr | Hexal AG |
Responsible Party: | Sandoz Biopharmaceuticals Development ( Hexal AG ) |
Study ID Numbers: | 2006-66-INJ-14 |
Study First Received: | February 29, 2008 |
Last Updated: | August 31, 2009 |
ClinicalTrials.gov Identifier: | NCT00632125 History of Changes |
Health Authority: | Austria: Federal Office for Safety in Health Care; Germany: Ministry of Health; Italy: The Italian Medicines Agency; Bulgaria: Bulgarian Drug Agency; United Kingdom: National Health Service; France: Afssaps - French Health Products Safety Agency; Macedonia: Ministry of Health; Poland: Ministry of Health; Romania: National Medicines Agency; Russia: Ministry of Health and Social Development of the Russian Federation; Ukraine: Ministry of Health |
CKD subjects with or without dialysis treatment |
Epoetin Alfa Renal Insufficiency Urologic Diseases Hematinics |
Renal Insufficiency, Chronic Kidney Failure, Chronic Kidney Diseases Kidney Failure |
Epoetin Alfa Renal Insufficiency Urologic Diseases Hematinics Renal Insufficiency, Chronic Therapeutic Uses |
Hematologic Agents Kidney Failure, Chronic Kidney Diseases Pharmacologic Actions Kidney Failure |